NCT00136526View on ClinicalTrials.gov

Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

October 31, 2007

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel and Diethylstilbestrol (DES)

Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.